Treatment options for Alzheimer's   Part 3 : What else do I need to know about eligibility and how to access treatment?  Lecanemab was proven effective at reducing Alzheimer’s-type plaques in the brain. Amyloid is measured in the brain using a specialized type of scan called amyloid PET. Research participants all had an amyloid PET scan showing evidence of these plaques before starting treatment. This scan was needed to prove that Alzheimer’s disease caused their cognitive im

Part 2: Am I eligible to take lecanemab? How can a neuropsychologist help to answer this question?   Lecanemab is effective in people with mild cognitive impairment and with early dementia caused by Alzheimer’s disease.   Investments in training over the last two decades have increased the capacity of general practitioners in Quebec to diagnose and treat dementia. However, it can be difficult to distinguish between normal age-related cognitive changes and the earliest stages

Finally! Note: This is Part 1 of a 3-part series of posts on the relevance of neuropsychological assessment in the context of lecanemab, a newly approved Alzheimer’s treatment.   Part 1: What is lecanemab and what does it do?   Health Canada recently approved lecanemab, a new treatment for Alzheimer’s disease. Lecanemab is also known by its brandname, Leqembi. This is exciting news because lecanemab is the first disease-modifying treatment approved in Canada for Alzheimer’s d